In this week’s episode, we cover a bacterium whose recent emergence and rapid spread has been largely an epidemic of our own making. Clostridium difficile isn’t your typical pathogen – in many cases it’s not even considered a pathogen, just a normal member of our gut microbiota. But when something disrupts our gut microbiota, like antibiotics, C. difficile is given the freedom to spread its wings, wreaking deadly havoc on our bodies especially when it refuses to leave. We explore the characteristics of this bacterium that make it such a terrifying public health threat, delve into its recent-but-not-as-recent-as-you-might-think history, and chat about the current status of C. diff before asking the question, “what can poo do for you?” That’s right, we’re taking this opportunity to talk about one of our all-time favorite medical interventions, fecal microbiota transplantation. Helping us navigate the ins and outs of fecal transplants is Dr. Majdi Osman, Chief Medical Officer at OpenBiome, a nonprofit stool bank that aims to expand access to safe fecal microbiota transplantation and fund research into the human microbiome. By the end of this episode, we think you’ll find yourself in awe at the healing powers of poop.
| History | Biology |
| Yong, Ed. I contain multitudes: The microbes within us and a grander view of life. Random House, 2016. | Leffler, D.A. and Lamont, J.T., 2015. Clostridium difficile infection. New England Journal of Medicine, 372(16), pp.1539-1548. |
| Bartlett, John G. “Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism.” Clinical Infectious Diseases 18.Supplement_4 (1994): S265-S272. | Crobach, M.J., Vernon, J.J., Loo, V.G., Kong, L.Y., Péchiné, S., Wilcox, M.H. and Kuijper, E.J., 2018. Understanding Clostridium difficile colonization. Clinical microbiology reviews, 31(2), pp.e00021-17. |
| Bartlett, John G. “Historical perspectives on studies of Clostridium difficile and C. difficile infection.” Clinical infectious diseases 46.Supplement_1 (2008): S4-S11. | Smits, W.K., Lyras, D., Lacy, D.B., Wilcox, M.H. and Kuijper, E.J., 2016. Clostridium difficile infection. Nature reviews Disease primers, 2(1), pp.1-20. |
| Borody, Thomas J., et al. “Bacteriotherapy using fecal flora: toying with human motions.” Journal of clinical gastroenterology 38.6 (2004): 475-483. | Czepiel, J., Dróżdż, M., Pituch, H., Kuijper, E.J., Perucki, W., Mielimonka, A., Goldman, S., Wultańska, D., Garlicki, A. and Biesiada, G., 2019. Clostridium difficile infection. European Journal of Clinical Microbiology & Infectious Diseases, 38(7), pp.1211-1221. |
| Dawson, Lisa F., Esmeralda Valiente, and Brendan W. Wren. “Clostridium difficile—a continually evolving and problematic pathogen.” Infection, Genetics and Evolution 9.6 (2009): 1410-1417. | Awad, M.M., Johanesen, P.A., Carter, G.P., Rose, E. and Lyras, D., 2014. Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen. Gut microbes, 5(5), pp.579-593. |
| De Groot, Pieter F., et al. “Fecal microbiota transplantation in metabolic syndrome: history, present and future.” Gut microbes 8.3 (2017): 253-267. | Lessa, F.C., Mu, Y., Bamberg, W.M., Beldavs, Z.G., Dumyati, G.K., Dunn, J.R., Farley, M.M., Holzbauer, S.M., Meek, J.I., Phipps, E.C. and Wilson, L.E., 2015. Burden of Clostridium difficile infection in the United States. New England Journal of Medicine, 372(9), pp.825-834. |
| Dingle, Kate E., et al. “Evolutionary history of the Clostridium difficile pathogenicity locus.” Genome biology and evolution 6.1 (2014): 36-52. | Balsells, E., Shi, T., Leese, C., Lyell, I., Burrows, J., Wiuff, C., Campbell, H., Kyaw, M.H. and Nair, H., 2019. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. Journal of global health, 9(1). |
| Gorbach, Sherwood L. “John G. Bartlett: Contributions to the discovery of Clostridium difficile antibiotic-associated diarrhea.” Clinical infectious diseases 59.suppl_2 (2014): S66-S70. | Goldenberg, J.Z., Yap, C., Lytvyn, L., Lo, C.K.F., Beardsley, J., Mertz, D. and Johnston, B.C., 2017. Probiotics for the prevention of Clostridium difficile‐associated diarrhea in adults and children. Cochrane Database of Systematic Reviews, (12). |
| Hall, Ivan C., and Elizabeth O’toole. “Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis.” American journal of diseases of children 49.2 (1935): 390-402. | Kitchin, N., Remich, S.A., Peterson, J., Peng, Y., Gruber, W.C., Jansen, K.U., Pride, M.W., Anderson, A.S., Knirsch, C. and Webber, C., 2020. A phase 2 study evaluating the safety, tolerability, and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy US adults aged 65 to 85 years. Clinical Infectious Diseases, 70(1), pp.1-10. |
| Khoruts, Alexander, and Michael J. Sadowsky. “Understanding the mechanisms of faecal microbiota transplantation.” Nature reviews Gastroenterology & hepatology 13.9 (2016): 508-516. | |
| Knight, Daniel R., and Thomas V. Riley. “Genomic delineation of zoonotic origins of Clostridium difficile.” Frontiers in public health 7 (2019): 164. | |
| Knight, Daniel R., et al. “Diversity and evolution in the genome of Clostridium difficile.” Clinical microbiology reviews 28.3 (2015): 721-741. | |
| Baron, Todd H., and Richard A. Kozarek. “Fecal microbiota transplant: we know its history, but can we predict its future?.” Mayo Clinic Proceedings. Vol. 88. No. 8. Elsevier, 2013. | |
| Kumar, Ranjit, et al. “Identification of donor microbe species that colonize and persist long term in the recipient after fecal transplant for recurrent Clostridium difficile.” NPJ biofilms and microbiomes 3.1 (2017): 1-4. | |
| Larson, H. Elliott, et al. “Clostridium difficile and the aetiology of pseudomembranous colitis.” The Lancet 311.8073 (1978): 1063-1066. | |
| Lewin, Ralph A. “More on merde.” Perspectives in Biology and Medicine 44.4 (2001): 594-607. | |
| Quinn, Thomas C., and Joel N. Blankson. “A tribute to John G. Bartlett, MD (1937–2021).” The Journal of clinical investigation 131.6 (2021). | |
| Rodriguez, Cristina, et al. “Clostridium difficile infection: early history, diagnosis and molecular strain typing methods.” Microbial Pathogenesis 97 (2016): 59-78. | |
| Rodríguez, C., et al. “Microbiota insights in Clostridium difficile infection and inflammatory bowel disease.” Gut Microbes 12.1 (2020): 1725220. | |
| Rodriguez-Palacios, Alex, et al. “Clostridium difficile in foods and animals: history and measures to reduce exposure.” Animal Health Research Reviews 14.1 (2013): 11-29. | |
| Schäffler, H., and A. Breitruck. “Clostridium difficile—from colonization to infection. Front Microbiol 9: 646.” (2018). | |
| Stabler, Richard A., et al. “Macro and micro diversity of Clostridium difficile isolates from diverse sources and geographical locations.” PloS one 7.3 (2012): e31559. | |
| Van Nood, Els, et al. “Duodenal infusion of donor feces for recurrent Clostridium difficile.” New England Journal of Medicine 368.5 (2013): 407-415. | |
| van Nood, Els, et al. “Fecal microbiota transplantation: facts and controversies.” Current opinion in gastroenterology 30.1 (2014): 34-39. | |
| Wang, Jiunn-Wei, et al. “Fecal microbiota transplantation: review and update.” Journal of the Formosan Medical Association 118 (2019): S23-S31. | |
| Young, Vincent B. “Therapeutic manipulation of the microbiota: past, present, and considerations for the future.” Clinical Microbiology and Infection 22.11 (2016): 905-909. | |
| Zhang, Faming, et al. “Should we standardize the 1,700-year-old fecal microbiota transplantation?.” The American journal of gastroenterology 107.11 (2012): 1755-author. |
Disclaimer: This post may contain affiliate links. If you buy something through one of these links, you won’t pay a penny more, but we’ll get a small commission which helps us keep things running. Thanks!
